Central Sector Scheme of Pharmacovigilance of Ayurveda, Siddha, Unani and Homoeopathy Drugs:

The Ministry of AYUSH has introduced new Central Sector scheme for promoting pharmacovigilance of Ayurveda, Siddha, Unani and Homoeopathy (ASU&H) Drugs. Prime objective of the scheme is to develop the culture of documenting adverse effects and undertake safety monitoring of Ayurveda, Siddha, Unani and Homoeopathy drugs and surveillance of misleading advertisements appearing in the print and electronic media.
The scheme intends to facilitate the establishment of three-tier network of National Pharmacovigilance Centre (NPvCC), Intermediary Pharmacovigilance Centres (IPvCCs) and Peripheral Pharmacovigilance Centres (PPvCC). All India Institute of Ayurveda, New Delhi, has been designated as National Pharmacovigilance Centre. In the initial phase of implementation, five National Institutes of AYUSH are designated as the Intermediary Pharmacovigilance Centres and forty-two (42) institutions of AYUSH having clinical facilities as Peripheral Pharmacovigilance Centres. It is intended to have more such centres across the country and achieve the target of 100 peripheral pharmacovigilance centres by 2020. Representatives of Central Drug Standards Control Organisation as the national drug regulatory authority and the Indian Pharmacopoeia Commission being the WHO Collaborating Centre for Pharmacovigilance in the country are associated in the initiative as mentor and guide.
Pharmacovigilance is more than spontaneous reporting alone and the evaluation of medicines is more than pharmacovigilance. It is the branch dealing with adverse drug reactions (ADRs), their recognition, and reporting. ADR is defined by the World Health Organization (WHO) as a response to a drug that is noxious, unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease or for the modification of a physiological function. Pharmacovigilance is defined by the WHO as a science, with activities that relate to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.
The common myth regarding herbal medicines is that these medicines are completely safe and can therefore be safely consumed by the patient on his/her own, without a physician’s prescription. This belief has led to large-scale self-medication by people all over the world, often leading to disappointing end-results, side effects, or unwanted aftereffects. Hence, AYUSH practitioners and consumers now need to be vigilant about the safety monitoring of drugs in the interest of Public Health.
Pharmacovigilance initiative will facilitate detection of potentially unsafe ASU&H medicines and misleading advertisements for taking regulatory action against them. The Standing Finance Committee (SFC) chaired by Secretary (AYUSH) approved the scheme on November 1, 2017 and subsequently it was rolled out for implementation in the country near the end of financial year 2017-18.
Aims and Objectives :
  • Early detection of unknown safety problems
  • Detection of increases in frequency
  • Identification of risk factors
  • Quantifying risks
  • Preventing patients from being affected unnecessarily.
Objectives of PV:
  • Promote a culture of safety awareness and ADR monitoring.
  • Identify signals of unknown ADRs.
Broad Objectives:
  • To foster the culture of AE notification and reporting.
  • To establish a viable and broad-based ADR monitoring program.
Specific Objectives:
  • To create an ADR database for the India population.
  • To create awareness of ADR monitoring among people.
  • To ensure optimum safety of drug product in Indian market.
  • To create infrastructure for ongoing regulatory review of periodic safety update reports.
Goals of Pharmacovigilance:
• The rational and safe use of medical drugs
• The assessment and communication of the risks and benefits of   drugs on the market
• Educating and informing of patients.

Peripheral Pharmacovigilance Centre (CBPACS)

Ch. Brahm Prakash Ayurved Charak Sansthan,Khera Dabar,New Delhi is working as a Peripheral pharmacovigilance centre since 2018 under the central scheme of Pharmacovigilance, Ministry of AYUSH, Govt. of India and has been working continuously with full dedication to achieve aims and objectives of the program. Dr. Subash Sahu, Associate professor & Head, department of Dravyaguna, is working as Co-ordinator for peripheral pharmacovigilancecentre, CBPACS.
Program Officials:
  1. Dr. Subash Sahu, Program Co-Ordinator, Room No. G22, Hospital block, Peripheral Pharmacovigilance Centre,Ch. Brahm Prakash Ayurved Charak Sansthan, khera Dabar, New Delhi -110073.
Email: , Contact No. – (+91) 9990537725.
  • Dr. Mohit Sharma, Program Assistant, Room No. G22, Hospital block, Peripheral Pharmacovigilance Centre, Ch. Brahm Prakash Ayurved Charak Sansthan, khera Dabar, New Delhi -110073.
Email: , Contact No. – (+91) 9650793236.

Awareness and Study Material

Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment.
When to report?
  • Simple message:Report as soon as you suspect that drug therapy has resulted in a negative, unintended effect
    • Speed is essential
What to report?
  • Adverse reactions
  • Lack of effect
  • counterfeiting
  • resistance
  • interaction
  • Quality problem
  • Dependence and abuse
  • Poisoning (?)
  • Medical error (?)
  • Serious reactions
  • Unexpected reactions
  • Unusually severe reactions
  • New medicines
Who can report?
  • Physicians
  • Nurses
  • Pharmacists
  • Medical students
  • Patients
How to report ?
  • As many channels as possible
    • Reporting by mail or Internet
      • Telephone service
      • Pick-up service
Methods to stimulate reporting by professionals
  • Facilitate access to reporting forms
  • Facilitate reporting
  • Acknowledge receipt of report
  • Feedback
  • Publication in medical journals
  • Participation in scientific conferences
How does ADR Reporting help!
Such findings can lead to changes in the marketing authorization of the medicine, e.g.:-
  • Restriction in use.
  • Changes in the dose of medicine.
  • Introduction of specific warning of side effects in product information sheet.

Size : 100 KB
Download the ADR form and fill it carefully and send the scanned copy of duly filled/complete form to

Last Updated Date :- 13-07-2021

  • India
  • govtprocurement
  • nvsp
  • digitalindia
  • digital-payments
  • Page last updated on: 09-10-2021